Filing Flows › Health Care › BioCorRx (BICX)
BioCorRx (BICX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · BioCorRx (BICX) Q2 2026 earnings results →
Q2 2026 Revenue down 51% year over year to $88K
BioCorRx made $88K in Q2 2026 (-51% Y/Y). Operating margin n/m, net loss $1.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $88K in Q2 2026, down 51% year over year and down 59% from the previous quarter.
Operating costs exceeded revenue by $1.5M, an operating margin of -1666.0%. Total costs fell 2% while revenue fell 51%. The fastest-growing cost line was Research & development (+140%). The quarter ended with a net loss of $1.0M, narrower than the previous quarter's $1.0M loss. Minority interests bore $37K of it: to shareholders the quarter was a loss of $1.0M. Non-operating items added $464K, -46% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$440K. Non-cash charges added back $10K of depreciation and amortization and $122K of share-based compensation. Working capital and other items added $429K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $88K | -51% | n/m | −$1.0M | −$440K |
| Q1 2026 | 10-Q | May 15, 2026 | $215K | +59% | -445.6% | −$860K | −$433K |
| Q3 2025 | 10-Q | Nov 14, 2025 | $635K | — | -306.3% | −$809K | −$634K |
| Q2 2025 | 10-Q | Aug 14, 2025 | $178K | 44× | -793.3% | −$1.4M | −$126K |
| Q1 2025 | 10-Q | May 15, 2025 | $135K | 37× | -695.3% | −$852K | −$690K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About BioCorRx
We were incorporated as Cetrone Energy Company on January 28, 2008 in the State of Nevada. From inception until we completed our reverse acquisition of Fresh Start Private, Inc. (“FSP”), the principal business of the Company originally was to develop “green” renewable fuel sources for agricultural operations, specifically biodiesel. On July 26, 2010, we filed an amendment to our articles of incorporation changing our name to Fresh Start Private Management, Inc. During that time, we had no revenue and our operations were limited to capital formation, organization, and development of our business plan and target customer market.
In its own words, from its 10-K, filed Mar 31, 2026.
BioCorRx against its Services-Specialty Outpatient Facilities, NEC peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -51% against the peers' median +5%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BICX BioCorRx | Q2 2026 | $88K | -51% | n/m |
| ACHC Acadia Healthcare Company | Q3 2026 | $895M | +5% | 6.3% |
| CON Concentra Group Holdings Parent | Q3 2026 | $622M | +9% | 18.5% |
| EHSI Elite Health Systems | Q2 2026 | $1.3M | — | -117.6% |
Source: BioCorRx 10-Q on SEC EDGAR · CIK 1443863 · Services-Specialty Outpatient Facilities, NEC
More on BICX
History
Every quarter: Q2 2026 results · Q1 2026 results · Q3 2025 results · Q2 2025 results · Q1 2025 results